Bio-Techne Corp.
(NASDAQ : TECH)

( )
TECH After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -6.72%174.070.0%$1639.17m
NVAXNovavax, Inc. -6.21%92.3378.2%$633.32m
AMGNAmgen, Inc. -1.08%231.301.4%$520.34m
BIIBBiogen, Inc. -1.28%230.811.8%$499.50m
GILDGilead Sciences, Inc. -1.93%69.071.0%$465.79m
BNTXBioNTech SE -4.47%161.660.0%$438.57m
REGNRegeneron Pharmaceuticals, Inc. 1.13%618.112.7%$392.67m
ILMNIllumina, Inc. 0.32%384.363.3%$386.08m
VRTXVertex Pharmaceuticals, Inc. -0.10%230.841.9%$334.35m
SNSSSunesis Pharmaceuticals, Inc. -4.00%2.880.7%$201.32m
EXASEXACT Sciences Corp. -1.67%76.1317.9%$160.64m
ARNAArena Pharmaceuticals, Inc. -0.51%91.5113.7%$138.71m
ALNYAlnylam Pharmaceuticals, Inc. -0.41%138.628.2%$131.51m
INCYIncyte Corp. -0.31%74.782.4%$129.60m
BBIOBridgeBio Pharma, Inc. -0.51%11.700.0%$104.26m

Company Profile

Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Protein Sciences and Diagnostics &Genomics. The Protein Sciences segment develops and manufactures purified proteins and reagent solutions most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. This segment also includes protein analysis solutions that offer researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics &Genomics segment develops and manufactures diagnostic products, including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx Prostate(IntelliScore) test (EPI) for prostate cancer diagnosis. This segment also manufactures and sells advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use. The company was founded in 1976 and is headquartered in Minneapolis, MN.